ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Protalix BioTherapeutics Treatment for Ulcerative Colitis Shows Positive Data
March 14, 2018Protalix Biotherapeutics, Inc. believes it’s on the right track in developing an oral medicine for ulcerative colitis that could potentially replace current TNF-inhibitor therapies that are administered via injection or infusion. -
US panel backs Pfizer’s Xeljanz for ulcerative colitis
March 12, 2018US regulatory advisors are backing use of Pfizer’s JAK inhibitor Xeljanz to treat adults with moderately to severely active ulcerative colitis (UC). -
US FDA accepts Pfizer’s sNDA for Xeljanz to treat ulcerative colitis
July 18, 2017The US Food and Drug Administration (FDA) has accepted for filing Pfizer’s supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate), an investigational oral solution to treat adult patients affected with moderately to severely active ulc
Pharma Sources Insight January 2025
